Surgical and oncological results after rectal resections with or without previous treatment for prostate cancer von Tomminen, T, Huhtala, H, Kotaluoto, S, Veitonmäki, T, Wirta, E-V, Hyöty, M

Volltext

Prostate cancer risk and nonsteroidal antiinflammatory drug use in the Finnish prostate cancer screening trial von Veitonmäki, T, Murtola, T J, Määttänen, L, Taari, K, Stenman, U-H, Tammela, T L J, Auvinen, A

Volltext

Critical evaluation of the Clavien-Dindo classification for postoperative complications in renal tumor surgery, a national multi-center study from Finland von Erkkilä, K., Veitonmäki, T., Ettala, E., Ronkainen, H., Isotalo, T., Nykopp, T., Seikkula, H., Seppänen, M., Tramberg, M., Palmberg Christian, C., Kilponen, A., Pogodin-Hannolainen, D., Mustonen, S., Nisen, H.

Volltext

Bispecific antibodies in cancer immunotherapy von Dahlén, Eva, Veitonmäki, Niina, Norlén, Per

Volltext

Adiponectin-Induced Antiangiogenesis and Antitumor Activity Involve Caspase-Mediated Endothelial Cell Apoptosis von Bråkenhielm, Ebba, Veitonmäki, Niina, Cao, Renhai, Kihara, Shinji, Matsuzawa, Yuji, Zhivotovsky, Boris, Funahashi, Tohru, Cao, Yihai, Kishimoto, Tadamitsu

Volltext

Prognostic factors of renal cell cancer in elderly patients: a population-based cohort study von Pajunen, Heini, Veitonmäki, Thea, Huhtala, Heini, Nikkola, Jussi, Pöyhönen, Antti, Murtola, Teemu

Volltext

Improved renal cancer prognosis among users of drugs targeting renin-angiotensin system von Eskelinen, Tommi, Veitonmäki, Thea, Kotsar, Andres, Tammela, Teuvo L. J., Pöyhönen, Antti, Murtola, Teemu J.

Volltext

The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation von Kvarnhammar, Anne Månsson, Veitonmäki, Niina, Hägerbrand, Karin, Dahlman, Anna, Smith, Karin Enell, Fritzell, Sara, von Schantz, Laura, Thagesson, Mia, Werchau, Doreen, Smedenfors, Kristine, Johansson, Maria, Rosén, Anna, Åberg, Ida, Winnerstam, Magnus, Nyblom, Eva, Barchan, Karin, Furebring, Christina, Norlén, Per, Ellmark, Peter

Volltext

Angiomotin Regulates Endothelial Cell-Cell Junctions and Cell Motility von Bratt, Anders, Birot, Olivier, Sinha, Indranil, Veitonmäki, Niina, Aase, Karin, Ernkvist, Mira, Holmgren, Lars

Volltext

A Human ICAM-1 Antibody Isolated by a Function-First Approach Has Potent Macrophage-Dependent Antimyeloma Activity In Vivo von Veitonmäki, Niina, Hansson, Markus, Zhan, Fenghuang, Sundberg, Annika, Löfstedt, Tobias, Ljungars, Anne, Li, Zhan-Chun, Martinsson-Niskanen, Titti, Zeng, Ming, Yang, Ye, Danielsson, Lena, Kovacek, Mathilda, Lundqvist, Andrea, Mårtensson, Linda, Teige, Ingrid, Tricot, Guido, Frendéus, Björn

Volltext

First‐in‐human study with intratumoral administration of a CD40 agonistic antibody, ADC‐1013, in advanced solid malignancies von Irenaeus, Sandra M. M., Nielsen, Dorte, Ellmark, Peter, Yachnin, Jeffrey, Deronic, Adnan, Nilsson, Anneli, Norlén, Per, Veitonmäki, Niina, Wennersten, Camilla S., Ullenhag, Gustav J.

Volltext

Non-Steroidal Anti-Inflammatory Drugs and Cancer Death in the Finnish Prostate Cancer Screening Trial von Veitonmäki, Thea, Murtola, Teemu J, Talala, Kirsi, Taari, Kimmo, Tammela, Teuvo, Auvinen, Anssi

Volltext

p130‐Angiomotin associates to actin and controls endothelial cell shape von Ernkvist, Mira, Aase, Karin, Ukomadu, Chinwe, Wohlschlegel, James, Blackman, Ryan, Veitonmäki, Niina, Bratt, Anders, Dutta, Anindya, Holmgren, Lars

Volltext

Sensitive Detection of Urothelial Cancer via High-volume Urine DNA Analysis von Nikkola, Jussi, Ryyppö, Lauri, Vuorinen, Juuso, Kallio, Heini, Selin, Hanna, Jämsä, Pyry, Åkerla, Jonne, Virtanen, Tuomo, Pekkarinen, Tarmo, Kaipia, Antti, Pulkkinen, Johanna, Vandekerkhove, Gillian, Müller, David C., Wyatt, Alexander W., Black, Peter C., Nykter, Matti, Veitonmäki, Thea, Annala, Matti

Volltext

Abstract 3251: Fibroblast activation protein (FAP)-selective delivery of CD40 agonistic DARPin®molecule for tumor-localized immune activation von Rigamonti, Nicolo, Schlegel, Anja, Barsin, Sophie, Schwestermann, Jonas, Mangold, Susanne, Kaufmann, Yvonne, Zitt, Christof, Veitonmäki, Niina, Levitsky, Victor, Metz, Clara

Volltext

The Bispecific Tumor Antigen-Conditional 4-1BB x 5T4 Agonist, ALG.APV-527, Mediates Strong T-Cell Activation and Potent Antitumor Activity in Preclinical Studies von Nelson, Michelle H, Fritzell, Sara, Miller, Robert, Werchau, Doreen, Van Citters, Danielle, Nilsson, Anneli, Misher, Lynda, Ljung, Lill, Bader, Robert, Deronic, Adnan, Chunyk, Allison G, Schultz, Lena, Varas, Laura A, Rose, Nadia, Håkansson, Maria, Gross, Jane, Furebring, Christina, Pavlik, Peter, Sundstedt, Anette, Veitonmäki, Niina, Ramos, Hilario J, Säll, Anna, Dahlman, Anna, Bienvenue, David, von Schantz, Laura, McMahan, Catherine J, Askmyr, Maria, Hernandez-Hoyos, Gabriela, Ellmark, Peter

Volltext

A Multispecific Anti-CD40 DARPin Construct Induces Tumor-Selective CD40 Activation and Tumor Regression von Rigamonti, Nicolò, Veitonmäki, Niina, Domke, Clara, Barsin, Sophie, Jetzer, Sarah, Abdelmotaleb, Omar, Bessey, Ralph, Lekishvili, Tamara, Malvezzi, Francesca, Gachechiladze, Mariam, Behe, Martin, Levitsky, Victor, Trail, Pamela A

Volltext

Abstract 2273: Selection of first-in-human clinical dose range for the tumor-targeted 4-1BB agonist MP0310 (AMG 506) using a pharmacokinetic/pharmacodynamics modeling approach von Link, Alexander, Juglair, Laurent, Poulet, Heïdi, Lemaillet, Guy, Reichen, Christian, Schildknecht, Patricia, Tosevski, Ivana, Robinson, Joanna, Veitonmäki, Niina, Herbst, Jörg, Dawson, Keith, Zitt, Christof, de Almeida, Camila, de Greef, Rik, Levitsky, Victor, Stumpp, Michael T., Ji, Hong, Baur, Elmar Vom

Volltext

Abstract 1073: A tumor-targeted CD40 agonistic DARPin® molecule leading to antitumor activity with limited systemic toxicity von Rigamonti, Nicolo, Jetzer, Sarah, Van der Velden, Niels, Abdelmotaleb, Omar, Barsin, Sophie, Schwestermann, Jonas, Mangold, Susanne, Kaufmann, Yvonne, Bessey, Ralph, Valeri, Andrea, Poulet, Heidi, Zitt, Christof, Trail, Pamela A., Levitsky, Victor, Veitonmäki, Niina, Metz, Clara

Volltext

The human agonistic CD40 antibody ADC-1013 eradicates bladder tumors and generates T-cell-dependent tumor immunity von Mangsbo, Sara M, Broos, Sissela, Fletcher, Erika, Veitonmäki, Niina, Furebring, Christina, Dahlén, Eva, Norlén, Per, Lindstedt, Malin, Tötterman, Thomas H, Ellmark, Peter

Volltext